{
    "id": 7584,
    "fullName": "JAK2 G935R",
    "impact": "missense",
    "proteinEffect": "gain of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "JAK2 G935R lies within the protein kinase domain 2 of the Jak2 protein (UniProt.org). G935R results in increased Jak2 and Stat5 phosphorylation, and prevents apoptosis in the presence of a Jak inhibitor (PMID: 22916261), and has been described as a secondary drug resistance mutation in the context of other Jak2 activating mutations (PMID: 22271575, PMID: 22916261), and therefore, is predicted to lead to a gain of Jak2 protein function.",
            "references": [
                {
                    "id": 3030,
                    "pubMedId": 22271575,
                    "title": "Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22271575"
                },
                {
                    "id": 3031,
                    "pubMedId": 22916261,
                    "title": "Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22916261"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 3717,
        "geneSymbol": "JAK2",
        "terms": [
            "JAK2",
            "JTK10",
            "THCYT3"
        ]
    },
    "variant": "G935R",
    "createDate": "06/13/2015",
    "updateDate": "10/22/2019",
    "referenceTranscriptCoordinates": {
        "id": 150806,
        "transcript": "NM_004972",
        "gDna": "chr9:g.5090487G>A",
        "cDna": "c.2803G>A",
        "protein": "p.G935R",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 21169,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing the JAK2 V617F and JAK2 G935R double mutation demonstrated resistance to Lestaurtinib (CEP-701) in culture (PMID: 21926964).",
            "molecularProfile": {
                "id": 7466,
                "profileName": "JAK2 V617F JAK2 G935R"
            },
            "therapy": {
                "id": 793,
                "therapyName": "Lestaurtinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3038,
                    "pubMedId": 21926964,
                    "title": "Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21926964"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21170,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing the JAK2 V617F and JAK2 G935R double mutation demonstrated resistance to Inrebic (fedratinib) in culture (PMID: 21926964).",
            "molecularProfile": {
                "id": 7466,
                "profileName": "JAK2 V617F JAK2 G935R"
            },
            "therapy": {
                "id": 911,
                "therapyName": "Fedratinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3038,
                    "pubMedId": 21926964,
                    "title": "Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21926964"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21164,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing the JAK2 V617F and JAK2 G935R double mutation demonstrated resistance to Momelotinib in culture (PMID: 21926964).",
            "molecularProfile": {
                "id": 7466,
                "profileName": "JAK2 V617F JAK2 G935R"
            },
            "therapy": {
                "id": 823,
                "therapyName": "Momelotinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3038,
                    "pubMedId": 21926964,
                    "title": "Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21926964"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2409,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 G935R double mutation demonstrated resistance to Jakafi (Ruxolitinib) in culture (PMID: 22271575).",
            "molecularProfile": {
                "id": 7466,
                "profileName": "JAK2 V617F JAK2 G935R"
            },
            "therapy": {
                "id": 907,
                "therapyName": "Ruxolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3030,
                    "pubMedId": 22271575,
                    "title": "Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22271575"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2412,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 G935R double mutation demonstrated resistance to NVP-BVB808 in culture (PMID: 22271575).",
            "molecularProfile": {
                "id": 7466,
                "profileName": "JAK2 V617F JAK2 G935R"
            },
            "therapy": {
                "id": 2834,
                "therapyName": "NVP-BVB808",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3030,
                    "pubMedId": 22271575,
                    "title": "Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22271575"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21167,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing the JAK2 V617F and JAK2 G935R double mutation demonstrated resistance to AZD1480 in culture (PMID: 21926964).",
            "molecularProfile": {
                "id": 7466,
                "profileName": "JAK2 V617F JAK2 G935R"
            },
            "therapy": {
                "id": 652,
                "therapyName": "AZD1480",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3038,
                    "pubMedId": 21926964,
                    "title": "Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21926964"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2411,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 G935R double mutation demonstrated resistance to NVP-BSK805 in culture (PMID: 22271575).",
            "molecularProfile": {
                "id": 7466,
                "profileName": "JAK2 V617F JAK2 G935R"
            },
            "therapy": {
                "id": 2785,
                "therapyName": "NVP-BSK805",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3030,
                    "pubMedId": 22271575,
                    "title": "Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22271575"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2410,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing the JAK2 R683G/G935R double mutation demonstrated resistance to Jakafi (Ruxolitinib) in culture (PMID: 22271575).",
            "molecularProfile": {
                "id": 7468,
                "profileName": "JAK2 R683G JAK2 G935R"
            },
            "therapy": {
                "id": 907,
                "therapyName": "Ruxolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3030,
                    "pubMedId": 22271575,
                    "title": "Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22271575"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2414,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing the JAK2 R683G/G935R double mutation demonstrated resistance to NVP-BVB808 in culture (PMID: 22271575).",
            "molecularProfile": {
                "id": 7468,
                "profileName": "JAK2 R683G JAK2 G935R"
            },
            "therapy": {
                "id": 2834,
                "therapyName": "NVP-BVB808",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3030,
                    "pubMedId": 22271575,
                    "title": "Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22271575"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2413,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing the JAK2 R683G/G935R double mutation demonstrated resistance to NVP-BSK805 in culture (PMID: 22271575).",
            "molecularProfile": {
                "id": 7468,
                "profileName": "JAK2 R683G JAK2 G935R"
            },
            "therapy": {
                "id": 2785,
                "therapyName": "NVP-BSK805",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3030,
                    "pubMedId": 22271575,
                    "title": "Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22271575"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5577,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, immune cells expressing ETV6-JAK2 with the G935R mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).",
            "molecularProfile": {
                "id": 21291,
                "profileName": "ETV6 - JAK2 JAK2 G935R"
            },
            "therapy": {
                "id": 2797,
                "therapyName": "Pyridone 6",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3031,
                    "pubMedId": 22916261,
                    "title": "Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22916261"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 7466,
            "profileName": "JAK2 V617F JAK2 G935R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 7467,
            "profileName": "JAK2 G935R",
            "profileTreatmentApproaches": [
                {
                    "id": 5334,
                    "name": "JAK2 Inhibitor",
                    "profileName": "JAK2 G935R"
                },
                {
                    "id": 5333,
                    "name": "JAK Inhibitor (Pan)",
                    "profileName": "JAK2 G935R"
                }
            ]
        },
        {
            "id": 7468,
            "profileName": "JAK2 R683G JAK2 G935R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 21291,
            "profileName": "ETV6 - JAK2 JAK2 G935R",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 150804,
            "transcript": "NM_001322195",
            "gDna": "chr9:g.5090487G>A",
            "cDna": "c.2803G>A",
            "protein": "p.G935R",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 150803,
            "transcript": "NM_001322194",
            "gDna": "chr9:g.5090487G>A",
            "cDna": "c.2803G>A",
            "protein": "p.G935R",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 150806,
            "transcript": "NM_004972",
            "gDna": "chr9:g.5090487G>A",
            "cDna": "c.2803G>A",
            "protein": "p.G935R",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 150805,
            "transcript": "NM_001322196",
            "gDna": "chr9:g.5090487G>A",
            "cDna": "c.2803G>A",
            "protein": "p.G935R",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}